screening for down syndrome

67

Upload: sadaf-khan

Post on 16-Apr-2017

582 views

Category:

Education


0 download

TRANSCRIPT

Page 1: screening for down syndrome
Page 2: screening for down syndrome

Dr nadia munir Tmo gynae c unit

LRH

Page 3: screening for down syndrome

Prenatal screening For down syndrome

Page 4: screening for down syndrome

contentsDefinationSignificance BackgroundIncidenceAntenatal screening First trimester screeningSecond trimester screening Down syndromeConclusion Take home message

Page 5: screening for down syndrome

The detection of abnormalities in the fetus, before birth’

Screening is the process of surveying a population, using a specific marker or markers to identify the individuals in the population at higher risk for a particular disorder.

Definition:

Page 6: screening for down syndrome

The purpose of prenatal diagnosis is not simply to detect abnormalities in fetal life and allow termination.It rather have following goals :

Page 7: screening for down syndrome

Provides information. Provide reassurance & remove anxiety. Confirmatory testing. Plan for appropriate management . Prenatal treatment of the fetus. Routinely offered. Always explain pros and cons.

Page 8: screening for down syndrome

High prevalence in the population. Knowledge about the disease and its progression. Highly sensitive and specific. Acceptable to population. Availability of other diagnostic test. Problem solution. Cost effective.

Principles for screening

Page 9: screening for down syndrome

National screening programmes were first introduced in UK 1996 and these includes :-

Screening for down syndrome. Fetal anomaly screening. Screening for sickle cell anemia and

thalassaemia. Screening for infectious diseases.

Background

Page 10: screening for down syndrome

DOWN SYNDROME John Langdon Down in 1866. 1930s research declared ____

chromosomal defect 1959,Jerome Lejune, discovered

an extra chromosome (trisomy) in DS individuals

Page 11: screening for down syndrome
Page 12: screening for down syndrome

Down syndrome is a chromosomal disorder. Error in cell division, the likelihood of such an

error occuring increases with maternal age.

This means that an older mother is more likely to give birth to a child with Down syndrome than her younger counterpart.

Incidence of Down’s Syndrome

Page 13: screening for down syndrome

The likelihood of a woman under 30 years of age giving birth to a child with Down syndrome is less than 1:1000, but increases the older the woman gets , with an incidence of about 1:100 and 1:30 at 40 and 45 years of age respectively.

Page 14: screening for down syndrome
Page 15: screening for down syndrome

STATISTICS

6000 infants/year are born with down syndrome

1979-2010 incidence is increased by 30%

In 2010,_____USA was about 250,700.

Page 16: screening for down syndrome

Genetic testing is on increase 5.3% of pregnancies with DS are conti… 90% of pregnancies e DS terminated in New

Zealand 92% in USA 93% in UK

STATISTICS….

Page 17: screening for down syndrome

17

INDICATIONS OF PRENATAL SCREENING

1. Advanced maternal age.2. Previous child with a chromosomal abnormality.3. Family history of a chromosomal abnormality.4. Family history of a single gene disorder.5. Family history of other congenital structural

abnormality.6. Abnormalities identified in pregnancy.7. Other risk factors(consanguinity,poor obs.

History,maternal history)

Page 18: screening for down syndrome

Time • 1st trimester• 2nd trimester

Technique• Non .Invasive• invasive

CLASSIFICATION….

Page 19: screening for down syndrome
Page 20: screening for down syndrome

Screening tests for down syndrome

Page 21: screening for down syndrome

21

METHODS OF PRENATAL SCREENING

NON INVASIVE TECHNIQUES

Fetal visualization Maternal serum

screening Separation of fetal

cells from the mother's blood

INVASIVE TECHNIQUES

Fetal visualization Fetal tissue

sampling Cytogenetics Molecular genetics

Page 22: screening for down syndrome

First Trimester ScreeningScreening methods-1. Age of mother.2. Ultrasonography 3. Maternal serum markers.4. Ductus venosus sonography.5. Tricuspid Regurgitation Doppler study.

Secondaryscreening tools

Page 23: screening for down syndrome

The only screening marker in 1970s

Age >35 years, amniocentesis was offered

<1/3rd of fetuses with trisomy 21 were identified

Maternal age

Page 24: screening for down syndrome

MATERNAL AGE RISK OF DS(newborn)

20years 1/1667

25years 1/1250

30 years 1/1000

35 years 1/385

40 years 1/100

45 years 1/30

Page 25: screening for down syndrome

25

FETAL VISUALISATION

ULTRASONOGRAPHY :

The developing embryo can first be visualized at about 6 weeks gestation.

Recognition of the major internal organs & extremities to determine if any are abnormal can best be accomplished between 16 to 20 weeks gestation.

Page 26: screening for down syndrome

Nuchal Translucency

• Nuchal Translucency(NT) refers to the normal subcutaneous fluid filled space between the back of the neck and underlying skin.

Page 27: screening for down syndrome

27

2D US

Page 28: screening for down syndrome

28

2D US

Page 29: screening for down syndrome

Nuchal TranslucencyNT measurement Chance of normal birth

≤ 3.4mm 95%

3.5 – 4.4mm 70-86%

4.5 – 5.4mm 50-77%

5.5 – 6.4mm 67%

≥ 6.5mm 31%

Page 30: screening for down syndrome

NT also increased in:

Trisomies 21, 18, 13.

Spontaneous fetal loss

Cardiac defects, diaphragmatic hernia, pulmonary defects.

skeletal dysplasias, congenital infection.

Normal pregnancy .

Page 31: screening for down syndrome

Nasal Bone (NB) Absent nasal bone on USG done at 11 to 13 weeks is another marker of Downs syndrome.

Absence of Nasal bone is not related to NT and can be combined in one scan. Detection rate of DS is 67%. When combined with NT detection rate is 90%.

Page 32: screening for down syndrome

32

2D US

Page 33: screening for down syndrome

33

2D US

Page 34: screening for down syndrome

34

3D & 4D US In recent years three-dimensional ultrasound (3D) &

four-dimensional ultrasound (4D) have started to play an increasing role in prenatal diagnosis. They can be applied in assessing facial features, central nervous system abnormalities and skeletal defects

Page 35: screening for down syndrome

35

Limitations in this procedure

Findings are based upon views of the fetus, the estimated gestational age, sonographer experience, & the degree of anomaly severity.

Page 36: screening for down syndrome

• Congenital heart lesions as early as 17-19 wk of gestation. • When this technique is used with duplex or color flow

Doppler, it can identify a number of major structural cardiac defects &• rhythm.• 59% to 93% of aneuploid fetus has abnormal ductus

venosus flow.• Down syndrome detection rate during 11 to 13 weeks is 68%

alone.

FETAL ECHO

Page 37: screening for down syndrome

First trimester Ductus venosus sonography.

• 1st Trimester Ductus venosus blood flow is an adjunctive test For fetal aneuploidy screening.• Forward triphasic pulsatile flow is normal. •Reversed flow at time of atrial contraction is abnormal.

Page 38: screening for down syndrome

First trimester Tricuspid Regurgitation(TR)

• Abnormal tricuspid regurgitation in 1st trimester is associated with fetal aneupoidy.• TR ______ if a regurgitant jet of at least 60cm/sec is noted extending to over half of systole.• Down syndrome detection rate during 11 to 13 weeks is 68% alone. • Not recommended for routine screening.• Has a role as second line screening test with detection rate of 92%.

Page 39: screening for down syndrome

39

MATERNAL SERUM SCREENING

Maternal serum screening is used to identify women at increased risk of having a child with trisomies 18 or 21

or and open neural tube defect (NTD), while posing no risk to the pregnancy.

Screening in the first trimester involves the measurement of PAPP & free b HCG levels in

maternal serum.

Page 40: screening for down syndrome
Page 41: screening for down syndrome

Comparison of Prenatal Screening Tests in Detecting Down Syndrome

Tests Detection Rate(DR)

False Positive Rate (FPR)

IPS 85 - 90% 2 - 4%

FTS 78 - 85% 3 - 9%

Quad 75 - 85% 5 - 10%

Triple 60 - 85% 5 - 12%

NT alone 60 - 70% 5%

Page 42: screening for down syndrome

Triple testDisorders MSAFP uE3 Beta hCG Inhibin A

Open NTD increased No change No change No change

Downs syndrome

decreased decreased increased Increased

Trisomy 18 decreased decreased No change No change

Page 43: screening for down syndrome

a protein synthesized by the fetus is detectable in maternal serum from week 6 of pregnancy,with a peak in week 34 of gestation (4 mg / ml), its value decreasing in 8-12 months after birth. Measurement of alpha-fetoprotein can be done from amniotic fluid or from maternal blood.

BIOCHEMICAL MARKERS PRENATAL DIAGNOSIS 1- Alpha-fetoprotein (AFP)

Page 44: screening for down syndrome

44

Contin... AFP is produced by the yolk sac & later by the liver; it

enters the amniotic fluid & then the maternal serum via fetal urine.

In the condition of an open NTD (eg, anencephaly, spina bifida) & abdominal wall defects in the fetus, AFP diffuses rapidly from exposed fetal tissues into amniotic fluid, and the MSAFP level rises

Page 45: screening for down syndrome

Conditions associated with abnormal level of MSAFPELEVATED LEVELS• Underestimation of gestation age. • Multifetal gestation.• IUD• NTD• Gastroschisis and omphalocele• Esophageal or intestinal obstruction.• sacrococcygeal teratoma.• Renal anomalies

LOW LEVELS• Overestimated gestational age•Obesty•Down syndrome•GTD•Fetal death

Page 46: screening for down syndrome

The hormone human chorionic gonadotropin is produced during pregnancy by synctiotrophoblast.

Its levels will double every 72 hours. The level will reach its peak in the first 8 – 11 weeks of pregnancy and then will decline and level off for the remainder of the pregnancy.

Human Chorionic Gonadotropin

Page 47: screening for down syndrome

3 weeks LMP: 5 – 50 mIU/ml 4 weeks LMP: 5 – 426 mIU/ml 5 weeks LMP: 18 – 7,340 mIU/ml 6 weeks LMP: 1,080 – 56,500 mIU/ml 7 – 8 weeks LMP: 7, 650 – 229,000 mIU/ml 9 – 12 weeks LMP: 25,700 – 288,000 mIU/ml 13 – 16 weeks LMP: 13,300 – 254,000 mIU/ml 17 – 24 weeks LMP: 4,060 – 165,400 mIU/ml 25 – 40 weeks LMP: 3,640 – 117,000 mIU/ml Non-pregnant females: <5.0 mIU/ml

Guideline to HCG levels during pregnancy/ LMP Last menstrual period

Page 48: screening for down syndrome

Estriol (E3) is one of the three major naturally occurring estrogens.

During pregnancy, estriol is secreted by the placenta and fetus and becomes the dominant estrogen form.

The primary form of estriol measured during pregnancy is unconjugated estriol .

Used in the evaluation of pregnancy complications.

Unconjugated estriol

Page 49: screening for down syndrome

Glycoprotein hormones .

Its a better marker of placental function than hcG because of its shorter half-life.

The measurement of inhibin A in early pregnancy could be in predicting miscarriage, Down's syndrome, preeclampsia, and fetal growth restriction in the first and/or second trimester.

Inhibin - A

Page 50: screening for down syndrome

It largest proteins produced by both the embryo and the placenta.

This protein have several different functions, including preventing recognition of the fetus by the maternal immune system, matrix mineralization and angiogenesis.

Detection of this protein helps in first and second trimester diagnostic test for aneuploidies, including Trisomies 21 or Down’s Syndrome

Pregnancy-associated plasma protein-A

Page 51: screening for down syndrome

51

Separation of fetal cells from the mother's blood

It involves isolating fetal cells from maternal blood to analyse fetal chromosomes and/or DNA. Ordinarily, only a very small number of fetal cells enter the maternal circulation; but once they enter,can be readily identified.

These cells can be collected safely from approximately 12-18 weeks' gestation onward.

Page 52: screening for down syndrome

52

Fetal blood cells can then be analyzed for the diagnosis of genetic disorders using FISH, PCR etc.

Fetal cells separated from a mother's blood have been successfully used in the diagnosis of cystic fibrosis, sickle cell anemia, and thalassemia in a fetus.

A. Maternal RBCs B. Fetal RBCs (nucleated)

Page 53: screening for down syndrome

Invasive • Amniocentesis• Chorionic villous sampling

Invasiveness..

Page 54: screening for down syndrome

54

INVASIVE TECHNIQUES Pre procedure genetic counseling- Pre procedure counseling is necessary as it will allow

patients to understand their situation allow them to give consent(or withhold) for the procedure.

Following points to be explained—

1. The chance that fetus will be affected.2. Nature and consequences of disorder.3. Risks and limitation of procedure.4. Time required for reporting.5. Possibility of complications.

Page 55: screening for down syndrome

55

Fetal Tissue Sampling Amniocentesis Chorionic villus sampling (CVS) Percutaneous umbilical blood sampling (PUBS) Percutaneous skin biopsy Other organ biopsies, including muscle & liver

biopsy

Page 56: screening for down syndrome

56

Amniocentesis : performed at 10-14 weeks but usually done at 15-18

weeks of gestation. pregnancy loss rate of 1 – 2 % & an increased

incidence of clubfoot.

A 22-gauge needle is passed through the mother's lower abdomen into the amniotic cavity inside the uterus, & 10-20 mL of amniotic fluid that contains cells from amnion, fetal skin, fetal lungs, and urinary tract epithelium are collected.

Page 57: screening for down syndrome

57

1. The Cells are grown in culture for chromosomal, biochemical,

& molecular biologic analyses.2. The Supernatant amniotic fluid is used for the

measurement of substances such as AFP, AChE,bilirubin & pulmonary surfactant

3. In the third trimester of pregnancy, the amniotic fluid can be analyzed for determination of fetal lung maturity.

The results of cytogenetic and biochemical studies on amniotic cell cultures are more than 90% accurate.

Page 58: screening for down syndrome

58

Chorionic villous sampling Under USG guidance, a sample of placental tissue is

obtained through a catheter places either transcervically or transabdominally.

Performed at or after 10 wks’ gestation, CVS provides the earliest possible detection of a

genetically abnormal fetus through analysis of trophoblast cells.

Page 59: screening for down syndrome

Transabdominal CVS can also be used as late as the 3rd trimester when amniotic fluid is not available or when fetal blood sampling cannot be performed.

CVS, if preformed before 10 wks’ gestation , can be ass. with an increased risk of fetal limb reduction defects & oromandibular malformations.

Page 60: screening for down syndrome

60

Direct preparations of rapidly dividing cytotrophoblasts

can be prepared, making a full karyotype analysis available in 2 days.

Although direct preparation minimize maternal cell contamination, most centers also analyse cultured trophoblast cells, which are embryologically closer to the fetus.This procedure takes 8 – 12 days.

Page 61: screening for down syndrome

In approximately 2% of CVS samples, both karyotypically normal & abnormal cells are identified. Because CVS acquired cells reflect placental constitution, in these cases, amniocentesis is typically performed as a followup study to analyze fetal cells. Approximatally 1/3rd of CVS mosaicisms are confirmed in the fetus through amniocentesis.

Page 62: screening for down syndrome

62

Cytogenetic Investigations

Chromosome Analysis ( Karyotype Analysis )

Fluorescence in situ Hybridization (FISH)

Page 63: screening for down syndrome

63

Direct DNA AnalysisLinkage Analysis(indirect DNA analysis)

DNA Sequencing

Molecular genetics

Page 64: screening for down syndrome

64

PRENATAL TREATMENT In the most situations the diagnosis of prenatal

abnormalities has a subsequent option of termination of the pregnancy.

While this applies in most situations, there is cautious optimism that with the advent of gene therapy prenatal diagnosis will, in time, lead to effective treatment in utero.

Page 65: screening for down syndrome

Genetic counseling • Clinical Genetics is the discipline concerned with the diagnosis and management of the medical, social, and psychological aspect of hereditary diseases.• Genetic counseling is an integral part of genetic testing /prenatal Testing.• The process of genetic counseling involves components like

1)validation of diagnosis2)obtaining the family history, 3)estimation of risk of recurrence 4)and by all these helping the family to reach

decisions and take appropriate action and follow up.• Nondirective counseling is adopted as standard, In this patients are not told what decision to make with regards to testing and management options but, instead, are provided information and support.

Page 66: screening for down syndrome
Page 67: screening for down syndrome